HERO™ provides emerging and established Biotech and Pharma Sponsors with a focused CRO solution and an integrated site network specializing in early phase oncology clinical studies. Our unique operation model propels you through the Proof of Concept phase faster and more efficiently, placing your cancer therapy on the road to success. HERO™ offers you the scale, expertise, and optimized technologies needed for your early phase oncology clinical research.
The oncology research field is getting more competitive and trial designs are increasing in complexity. The pace of novel ideas continues to accelerate with rapid advancements in technology, science, and medicine. More frequently, cancer therapies are targeting small subsets of patients with rare mutations or patients that have been treated with a very specific therapeutic regimen. We understand your job is hard, and thus HERO™ was born to make the trial process easier. Whether you have a biomarker targeted therapy and or a combination immuno-oncology trial, HERO™ has you covered.
HERO™ is a complete service offering, dedicated solely to advancing early phase cancer clinical trials. Our integrated CRO and site solutions get you the patients you need, faster than ever before. We have created automated technologies and systems, tailored to early phase oncology studies, to expedite your trial while keeping costs down. The HERO™ team of oncology experts work with you to customize your protocol and study design for an optimal outcome. Our goal is to get you through that critical early stage of testing and on your way to FDA approval, with the shared mission of bringing products to market that save lives.
We provide our clients with the scale, expertise, and senior management commitment to maintain immediate and consistent engagement with your team at all times throughout the course of your program, to ensure the successful execution and delivery of your proof of concept studies. HERO™ is our pledge to create more fruitful relationships, deliver a higher degree of therapeutic expertise, and the opportunity to do better, more efficient cancer clinical research.
Accelovance's extensive oncology site network includes 250 independently owned research locations across the globe with more than 1,000 Oncologists. With access to a wide variety of specialties and expertise, we can provide both broad based feasibility and unique access to the right oncology patients your study needs.
Most cancer CROs average 6-9 months for early phase trial start-ups. But when time is of the essence, and every lost day can cost upwards of $1MM, we know how critical a simple, thorough, streamlined start-up is to your oncology development program. Our goal is to help expedite getting your cancer therapy on the market.
With our extensive array of 250+ global site partners, each year our site community reaches more than 1 million cancer patients spanning a wide range of indications. This reach, combined with our CRO's operational experitse, provides an ideal backbone and facilitates rapid activation of your clinical program.
Our novel solutions are designed to meet the unique demands of your Phase I/II oncology study. From Regulatory to Data Management, and from Monitoring to Pharmacovigilance, our solutions are cross-functional and accelerate access, ensuring data accuracy and compliance, and improving cost efficiency.
With HERO™, you get a so much more than an oncology CRO. You get true partners to guide you through the hurdles and nuances of oncology clinical research. From pre-study design, to enrolling the right patients, to oversight of you phase 1 trial for cancer, with HERO™ you get the industry expertise of a large CRO without the lofty price tag. Our senior management and scientific experts are is as committed to your oncology compound's success as you are, meaning we are dedicated to being there before, during, and after your trial. Learn more about the team below.
Dr. Jamie Oliver, Chief Scientific Officer, has supported more than 25 FDA submissions (IND to NDA) for oncology drugs and biologics. His extensive experience covers biologics, small molecule and nanoparticle oncology products. His breadth of work allows him to effectively guide Sponsors to optimize your programs from pre-clinical to NDA. Dr. Oliver provides input and development strategies as part of Accelovance's oncology consulting team in collaboration with Harish Dave, Chief Medical Officer.
Dr. Harish Dave, board certified oncologist, has been involved in over 100 clinical trials. He leads our Medical Affairs & Drug Safety group where he leverages over 25 years' experience gained from academia, as a principal investigator, and industry professional. Dr. Dave provides input and development within our Oncology consulting team along with Jamie Oliver, Chief Scientific Officer.
Accelovance is an award-winning, clinical development CRO focused on oncology and immunological vaccine programs across phase I-IV. The HERO Initiative by Accelovance is a specialized early phase oncology program providing emerging and established biotech and pharmaceutical companies an accelerated means of advancing their early phase cancer compounds through clinical testing. Learn more about our services: